News - Infinity Pharmaceuticals, Research


Popular Filters

Infinity plunges as it halts two saridegib trials


US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) saw its shares plummet 20% to $11 in pre-marketing…

Infinity PharmaceuticalsIPI-145MundipharmaOncologyPharmaceuticalResearchretaspimycinsaridegib

Mundipharma commits over $50 million in R&D funding for Infinity’s PI3K inhibitor


Privately-held Mundipharma International as committed to providing over $50 million in funding in 2013…

FinancialInfinity PharmaceuticalsInflammatory diseasesLicensingMundi InternationalOncologyPharmaceuticalResearch

Back to top